Business Wire

EUSA-PHARMA

2.7.2020 10:02:10 CEST | Business Wire | Press release

Share
EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome

EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).

Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling.

Lee Morley , Chief Executive Officer , EUSA Pharma , said: “Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production – the so-called ‘cytokine storm’ – with IL-6 recognized as a key driver of this severe condition. Treatment approaches neutralizing IL-6 could therefore play a key role in mitigating further detrimental inflammation and progression to respiratory failure, which can be fatal. We thank the FDA for recognizing the importance of this clinical trial and the quick approval we received. Our plan now is to initiate the study as quickly as possible with the hope of seeing improved clinical outcomes in these critically ill patients.”

To date, several independent clinical trials have begun globally to explore the safety and efficacy of siltuximab for the treatment of severe COVID-19 patients. Final results from the Papa Giovanni XXIII Hospital sponsored SISCO 1 (S iltuximab I n S erious CO VID-19) Study, an observational cohort control trial investigating siltuximab plus standard of care in COVID-19 patients with serious respiratory complications, are available via pre-print summary here .2 However, the newly approved confirmatory clinical trial is vital because these findings require validation in a well-controlled randomized study and there is limited published data on the safety and efficacy of siltuximab in COVID-19. Siltuximab is also not yet FDA-approved for complications associated with COVID-19.

About the New Clinical Trial

EUSA Pharma has received FDA approval to proceed with a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated ARDS, compared to placebo plus standard of care. The multicentre trial will aim to enrol approximately 400 patients with viral ARDS and elevated serum levels of IL-6. The primary objective is to evaluate all-cause mortality at 28 days with the addition of siltuximab to standard of care, compared to placebo plus standard of care. Secondary objectives include: time to 7-category ordinal scale of clinical status improvement, ventilator-free days within 28 days, organ failure-free days, intensive care unit length of stay, hospital length of stay, lung function and radiographic improvement.

About SYLVANT® ▼ (siltuximab)

SYLVANT is an IL-6 targeted monoclonal antibody approved by the FDA and the European Medicines Agency (EMA) as well as regulatory bodies in a number of other jurisdictions worldwide, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative (also known as idiopathic MCD). EUSA Pharma has exclusive rights to SYLVANT globally. EUSA Pharma has granted BeiGene, Ltd., exclusive development and commercialization rights to SYLVANT in Greater China.

SYLVANT is not licensed for the treatment of COVID-19.

Indications and Usage of SYLVANT – See Full Prescribing Information for Additional Details .

SYLVANT is indicated for the treatment of patients with MCD who are HIV negative and HHV-8 negative.

Limitations of Use: SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.

Contraindications : Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT.

Dosage and Administration

Administer SYLVANT 11 mg/kg over 1 hour as an intravenous infusion every 3 weeks until failure.

Perform hematology laboratory tests prior to each dose of SYLVANT therapy for the first 12 months and every 3 dosing cycles thereafter. If treatment criteria outlined in the Prescribing Information are not met, consider delaying treatment with SYLVANT. Do not reduce dose.

Do not administer SYLVANT to patients with severe infections until the infection resolves.

Discontinue SYLVANT in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions, or cytokine release syndromes. Do not reinstitute treatment.

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in select other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies, and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information please visit: www.eusapharma.com .

References

1 An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications (SISCO) [NCT04322188]: https://www.clinicaltrials.gov/ct2/show/NCT04322188

2 IL-6 Signalling Pathway Inactivation With Siltuximab in Patients With COVID-19 Respiratory Failure: an Observational Cohort Study. Gritti et al; medRxiv 2020.04.01.20048561; doi: https://doi.org/10.1101/2020.04.01.20048561

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 07:00:00 CET | Press release

RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co

Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 07:00:00 CET | Press release

Pilot completed with DBS and Franklin Templeton via Ant’s WhaleRTP platformWhitepaper launched detailing Whale Orchestration Protocol framework and its development under BLOOM Field GuideSolution achieves Singapore’s first successful cross-asset interoperability between tokenised deposits and tokenised money market funds Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and token

NETS and Ant International Deepen Partnership to Empower Singapore’s Businesses for a Future in Agentic Commerce with Agentic Mobile Protocol19.11.2026 06:30:00 CET | Press release

NETS becomes the first national payment rail to join Ant International’s Agentic Mobile ProtocolNETS and Ant International’s MOU signing signals commitment to deepen the companies’ long-standing collaboration since 2023The partnership aims to deliver comprehensive AI-native merchant solutions to expand reach and lift operational efficiency Network for Electronic Transfers (NETS), Singapore’s leading payment services group, and Ant International are deepening their partnership to help businesses across Singapore reach new customers, simplify their operations and thrive in the era of agentic commerce by building a more connected mobile ecosystem well adapted to the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118997808/en/ Lawrence Chan, Group CEO, NETS (L) and Peng Yang, CEO, Ant International (R) NETS and Ant International signed a Memorandum of Understanding (MOU) at the Singapore Fintech Festival 2026 to explo

SBC Medical Group Reports Cybersecurity Incidents in Japan19.11.2026 05:39:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical Group" or the "Company"), a provider of comprehensive management services to medical corporations and their clinics, today reported the occurrence of recent cybersecurity incidents involving customer information associated with certain clinics in Japan, along with the status of its response. Overview of the Incidents On November 16, 2026, unauthorized access occurred to certain databases within a website system managed and operated by SBC Medical Group, Ltd., the Company’s, Japanese subsidiary, in connection with its management services in Japan. The Company confirmed that an unauthorized third party accessed and extracted customer information. The method of intrusion and full scope remain under investigation. Based on current information, the information obtained and the number of affected customers are as follows: Category Types of information Individuals Period Basic personal information (without reservation or trea

Lenovo Group: Q2 Financial Results 2026/2719.11.2026 05:20:00 CET | Press release

Lenovo delivers record Q2 performance, confident in long-term Hybrid AI opportunities Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported second quarter results for fiscal year 2026/27, demonstrating strong growth, a leap forward in profitability, and structural enhancements to the Group’s business fundamentals. Overall Group revenue for the second quarter reached an all-time high of US$30.2 billion, up 48% year-on-year. All business groups delivered record second-fiscal-quarter revenue while demonstrating strong profitability, with the Infrastructure Solutions Group (ISG) becoming an engine of hyper-growth with operating profit surpassing US$1 billion for the first time. Adjusted net income[1]was up 166% year-on-year to US$1.4 billion, with adjusted net margin improvements of two percentage points year-on-year. AI-related revenue[2] grew 79% year-on-year, surpassing the US$10 billion mark for the first time and accounting for 36%

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye